Novo Financial Statements From 2010 to 2024

NVO Stock  USD 128.40  0.35  0.27%   
Novo Nordisk financial statements provide useful quarterly and yearly information to potential Novo Nordisk AS investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Novo Nordisk financial statements helps investors assess Novo Nordisk's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Novo Nordisk's valuation are summarized below:
Gross Profit
148.5 B
Profit Margin
0.3603
Market Capitalization
574.2 B
Enterprise Value Revenue
2.4564
Revenue
232.3 B
We have found one hundred twenty available fundamental ratios for Novo Nordisk, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Novo Nordisk's last-minute fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road.
Check Novo Nordisk financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novo main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.9 B, Interest Expense of 429.4 M or Selling General Administrative of 6.5 B, as well as many exotic indicators such as Short Term Coverage Ratios of 21.88, Price Earnings Ratio of 39.29 or Price To Sales Ratio of 14.16. Novo financial statements analysis is a perfect complement when working with Novo Nordisk Valuation or Volatility modules.
  
This module can also supplement Novo Nordisk's financial leverage analysis and stock options assessment as well as various Novo Nordisk Technical models . Check out the analysis of Novo Nordisk Correlation against competitors.

Novo Nordisk Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets330.2 B314.5 B135.9 B
Slightly volatile
Short and Long Term Debt Total28.4 B27 B8.6 B
Slightly volatile
Other Current Liabilities31.5 B30 B21.5 B
Slightly volatile
Total Current Liabilities178.1 B169.7 B65.9 B
Slightly volatile
Total Stockholder Equity111.9 B106.6 B56.9 B
Slightly volatile
Property Plant And Equipment Net95.5 B91 B42.2 B
Slightly volatile
Retained Earnings110.1 B104.8 B56.4 B
Slightly volatile
Cash8.1 B14.4 B13.1 B
Pretty Stable
Non Current Assets Total183.6 B174.8 B68.3 B
Slightly volatile
Cash And Short Term Investments31.7 B30.2 B18.2 B
Slightly volatile
Net Receivables79 B75.3 B31.8 B
Slightly volatile
Common Stock Shares Outstanding3.7 B4.5 B3.8 B
Slightly volatile
Liabilities And Stockholders Equity330.2 B314.5 B135.9 B
Slightly volatile
Non Current Liabilities Total40.2 B38.3 B13.1 B
Slightly volatile
Inventory33.4 B31.8 B16.4 B
Slightly volatile
Total Liabilities218.3 B207.9 B79 B
Slightly volatile
Property Plant And Equipment Gross145.5 B138.6 B53 B
Slightly volatile
Total Current Assets146.6 B139.6 B67.7 B
Slightly volatile
Short Term Debt6.8 B6.5 B2.8 B
Slightly volatile
Intangible Assets58.7 B55.9 B16.4 B
Slightly volatile
Accounts Payable26.9 B25.6 B8.6 B
Slightly volatile
Common Stock Total Equity493.1 M423 M520 M
Slightly volatile
Common Stock478.4 M451 M519.4 M
Slightly volatile
Other Liabilities15.1 B14.4 B5.7 B
Slightly volatile
Property Plant Equipment80.5 B76.7 B35.3 B
Slightly volatile
Current Deferred Revenue129.9 B123.7 B42.5 B
Slightly volatile
Other Assets16.2 B15.4 B5.5 B
Slightly volatile
Net Tangible Assets37 B36.9 B28.9 B
Slightly volatile
Long Term Investments1.5 B1.7 B1.2 B
Slightly volatile
Net Invested Capital87.7 B127.8 B67.1 B
Slightly volatile
Capital Stock374.5 M451 M473.6 M
Slightly volatile

Novo Nordisk Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization9.9 B9.4 B4.6 B
Slightly volatile
Selling General Administrative6.5 B4.9 B3.9 B
Slightly volatile
Total Revenue243.9 B232.3 B120.5 B
Slightly volatile
Gross Profit206.3 B196.5 B101 B
Slightly volatile
Other Operating Expenses136.2 B129.7 B69.6 B
Slightly volatile
Operating Income107.7 B102.6 B50.9 B
Slightly volatile
EBIT108.7 B103.5 B51 B
Slightly volatile
EBITDA118.6 B112.9 B55.7 B
Slightly volatile
Cost Of Revenue37.6 B35.8 B19.5 B
Slightly volatile
Total Operating Expenses98.6 B93.9 B50.2 B
Slightly volatile
Income Before Tax109.9 B104.7 B49.9 B
Slightly volatile
Net Income87.9 B83.7 B39.8 B
Slightly volatile
Income Tax Expense22 B21 B10.2 B
Slightly volatile
Research Development34.1 B32.4 B16.3 B
Slightly volatile
Net Income Applicable To Common Shares67 B63.9 B32.1 B
Slightly volatile
Selling And Marketing Expenses32.3 B56.7 B30.3 B
Slightly volatile
Net Income From Continuing Ops87.9 B83.7 B34.4 B
Slightly volatile
Tax Provision12.8 B21 B10.7 B
Slightly volatile
Interest Income1.2 B1.1 B2.9 B
Slightly volatile
Reconciled Depreciation6.5 B9.4 B4.7 B
Slightly volatile

Novo Nordisk Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Free Cash Flow73.5 B70 B36.3 B
Slightly volatile
Begin Period Cash Flow8.4 B12.7 B12.7 B
Pretty Stable
Depreciation9.9 B9.4 B4.6 B
Slightly volatile
Capital Expenditures40.8 B38.9 B12.5 B
Slightly volatile
Total Cash From Operating Activities114.4 B108.9 B48.7 B
Slightly volatile
Net Income87.9 B83.7 B39.8 B
Slightly volatile
End Period Cash Flow8.9 B14.4 B12.9 B
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Short Term Coverage Ratios21.8816.81250.913
Pretty Stable
Price Earnings Ratio39.2937.41821.2751
Slightly volatile
Price To Sales Ratio14.1613.48166.9915
Slightly volatile
Dividend Yield0.01780.01010.0233
Slightly volatile
Operating Cycle280443374
Slightly volatile
Price Book Value Ratio30.8529.384614.8636
Slightly volatile
Days Of Payables Outstanding274261138
Slightly volatile
Operating Cash Flow Per Share25.5124.294612.0046
Slightly volatile
Dividend Payout Ratio0.260.37960.4103
Slightly volatile
Price To Operating Cash Flows Ratio30.1928.751317.5456
Slightly volatile
Free Cash Flow Per Share16.415.61799.0664
Slightly volatile
Price To Free Cash Flows Ratio46.9644.724424.3699
Slightly volatile
Pretax Profit Margin0.470.45070.394
Slightly volatile
Inventory Turnover1.711.12431.285
Slightly volatile
Ebt Per Ebit1.191.02051.0038
Very volatile
Payables Turnover1.331.39673.0641
Slightly volatile
Operating Profit Margin0.460.44160.4004
Slightly volatile
Effective Tax Rate0.30.20050.2206
Pretty Stable
Company Equity Multiplier3.12.95122.1911
Slightly volatile
Long Term Debt To Capitalization0.110.16150.0824
Slightly volatile
Cash Per Share7.086.74364.8193
Pretty Stable
Total Debt To Capitalization0.140.20220.0888
Slightly volatile
Interest Coverage204189268
Very volatile
Return On Capital Employed0.740.70820.7095
Slightly volatile
Payout Ratio0.260.37960.4103
Slightly volatile
Debt Equity Ratio0.180.25340.1102
Slightly volatile
Ebit Per Revenue0.460.44160.4004
Slightly volatile
Quick Ratio0.590.62180.969
Slightly volatile
Net Income Per E B T0.580.79950.7714
Very volatile
Cash Ratio0.08060.08480.3788
Slightly volatile
Cash Conversion Cycle207182254
Pretty Stable
Operating Cash Flow Sales Ratio0.490.46890.3731
Slightly volatile
Days Of Inventory Outstanding214325289
Slightly volatile
Days Of Sales Outstanding66.3711885.0926
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.420.64290.725
Very volatile
Cash Flow Coverage Ratios3.834.032741.3815
Slightly volatile
Price To Book Ratio30.8529.384614.8636
Slightly volatile
Current Ratio0.780.82311.3252
Slightly volatile
Fixed Asset Turnover1.712.55342.9343
Slightly volatile
Price Cash Flow Ratio30.1928.751317.5456
Slightly volatile
Enterprise Value Multiple29.2327.836614.9217
Slightly volatile
Debt Ratio0.10.08590.0476
Slightly volatile
Cash Flow To Debt Ratio3.834.032741.3815
Slightly volatile
Price Sales Ratio14.1613.48166.9915
Slightly volatile
Return On Assets0.140.26610.2898
Pretty Stable
Receivables Turnover5.313.08614.4664
Slightly volatile
Asset Turnover0.660.73850.9497
Slightly volatile
Net Profit Margin0.380.36030.3114
Slightly volatile
Gross Profit Margin0.580.8460.797
Pretty Stable
Price Fair Value30.8529.384614.8636
Slightly volatile
Return On Equity0.820.78530.6489
Slightly volatile

Novo Fundamental Market Drivers

Forward Price Earnings38.1679
Cash And Short Term Investments30.2 B

Novo Upcoming Events

31st of January 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
31st of January 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Novo Nordisk Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Novo Nordisk income statement, its balance sheet, and the statement of cash flows. Novo Nordisk investors use historical funamental indicators, such as Novo Nordisk's revenue or net income, to determine how well the company is positioned to perform in the future. Although Novo Nordisk investors may use each financial statement separately, they are all related. The changes in Novo Nordisk's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Novo Nordisk's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Novo Nordisk Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Novo Nordisk. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2024
Current Deferred Revenue123.7 B129.9 B
Total Revenue232.3 B243.9 B
Cost Of Revenue35.8 B37.6 B
Ebit Per Revenue 0.44  0.46 

Novo Nordisk Investors Sentiment

The influence of Novo Nordisk's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Novo. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Novo Nordisk's public news can be used to forecast risks associated with an investment in Novo. The trend in average sentiment can be used to explain how an investor holding Novo can time the market purely based on public headlines and social activities around Novo Nordisk AS. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Novo Nordisk's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Novo Nordisk's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Novo Nordisk's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Novo Nordisk.

Novo Nordisk Implied Volatility

    
  26.87  
Novo Nordisk's implied volatility exposes the market's sentiment of Novo Nordisk AS stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Novo Nordisk's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Novo Nordisk stock will not fluctuate a lot when Novo Nordisk's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novo Nordisk in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novo Nordisk's short interest history, or implied volatility extrapolated from Novo Nordisk options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:
Check out the analysis of Novo Nordisk Correlation against competitors.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Novo Stock analysis

When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Bonds Directory
Find actively traded corporate debentures issued by US companies
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Commodity Directory
Find actively traded commodities issued by global exchanges
Is Novo Nordisk's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.631
Dividend Share
9.4
Earnings Share
2.7
Revenue Per Share
51.812
Quarterly Revenue Growth
0.37
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.